Daré Bioscience (DARE) Competitors $2.89 0.00 (0.00%) Closing price 05/21/2025 04:00 PM EasternExtended Trading$2.90 +0.01 (+0.52%) As of 05/21/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock DARE vs. SGMT, IVVD, MGNX, BDTX, CTNM, ENTX, KYTX, OPTN, HLVX, and IMUXShould you be buying Daré Bioscience stock or one of its competitors? The main competitors of Daré Bioscience include Sagimet Biosciences (SGMT), Invivyd (IVVD), MacroGenics (MGNX), Black Diamond Therapeutics (BDTX), Contineum Therapeutics (CTNM), Entera Bio (ENTX), Kyverna Therapeutics (KYTX), OptiNose (OPTN), HilleVax (HLVX), and Immunic (IMUX). These companies are all part of the "pharmaceutical products" industry. Daré Bioscience vs. Sagimet Biosciences Invivyd MacroGenics Black Diamond Therapeutics Contineum Therapeutics Entera Bio Kyverna Therapeutics OptiNose HilleVax Immunic Daré Bioscience (NASDAQ:DARE) and Sagimet Biosciences (NASDAQ:SGMT) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability, community ranking, media sentiment and analyst recommendations. Which has more risk and volatility, DARE or SGMT? Daré Bioscience has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500. Comparatively, Sagimet Biosciences has a beta of 2.32, indicating that its stock price is 132% more volatile than the S&P 500. Which has preferable earnings & valuation, DARE or SGMT? Sagimet Biosciences has higher revenue and earnings than Daré Bioscience. Daré Bioscience is trading at a lower price-to-earnings ratio than Sagimet Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDaré Bioscience$9.78K2,614.11-$30.16M-$0.17-17.00Sagimet Biosciences$2M49.39-$27.88M-$1.76-1.83 Does the media favor DARE or SGMT? In the previous week, Daré Bioscience had 4 more articles in the media than Sagimet Biosciences. MarketBeat recorded 6 mentions for Daré Bioscience and 2 mentions for Sagimet Biosciences. Daré Bioscience's average media sentiment score of 0.54 beat Sagimet Biosciences' score of 0.00 indicating that Daré Bioscience is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Daré Bioscience 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sagimet Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders and institutionals have more ownership in DARE or SGMT? 6.7% of Daré Bioscience shares are owned by institutional investors. Comparatively, 87.9% of Sagimet Biosciences shares are owned by institutional investors. 4.0% of Daré Bioscience shares are owned by company insiders. Comparatively, 14.7% of Sagimet Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the MarketBeat Community prefer DARE or SGMT? Daré Bioscience received 331 more outperform votes than Sagimet Biosciences when rated by MarketBeat users. However, 96.43% of users gave Sagimet Biosciences an outperform vote while only 73.36% of users gave Daré Bioscience an outperform vote. CompanyUnderperformOutperformDaré BioscienceOutperform Votes35873.36% Underperform Votes13026.64% Sagimet BiosciencesOutperform Votes2796.43% Underperform Votes13.57% Is DARE or SGMT more profitable? Sagimet Biosciences has a net margin of 0.00% compared to Daré Bioscience's net margin of -191.65%. Daré Bioscience's return on equity of 0.00% beat Sagimet Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Daré Bioscience-191.65% N/A -18.98% Sagimet Biosciences N/A -23.63%-22.91% Do analysts recommend DARE or SGMT? Daré Bioscience currently has a consensus target price of $12.00, suggesting a potential upside of 315.22%. Sagimet Biosciences has a consensus target price of $22.40, suggesting a potential upside of 595.65%. Given Sagimet Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Sagimet Biosciences is more favorable than Daré Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Daré Bioscience 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Sagimet Biosciences 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 SummarySagimet Biosciences beats Daré Bioscience on 11 of the 18 factors compared between the two stocks. Get Daré Bioscience News Delivered to You Automatically Sign up to receive the latest news and ratings for DARE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DARE vs. The Competition Export to ExcelMetricDaré BiosciencePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$25.58M$6.52B$5.37B$8.39BDividend YieldN/A2.65%5.22%4.10%P/E Ratio-4.898.9226.8419.71Price / Sales2,614.11253.80392.34117.39Price / CashN/A65.8538.2534.62Price / Book-4.746.466.794.50Net Income-$30.16M$143.98M$3.23B$248.18M7 Day Performance0.35%2.03%1.53%0.20%1 Month Performance-3.34%4.11%10.06%12.37%1 Year Performance-39.79%-2.87%16.72%7.04% Daré Bioscience Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DAREDaré Bioscience1.3921 of 5 stars$2.89flat$12.00+315.2%-43.3%$25.58M$9,784.00-4.8930SGMTSagimet Biosciences1.5742 of 5 stars$3.31+1.5%$22.40+576.7%-32.8%$101.53M$2M-2.318Positive NewsGap UpIVVDInvivyd2.9191 of 5 stars$0.84+29.7%$7.52+797.2%-65.4%$100.50M$25.38M-0.43100Earnings ReportGap DownMGNXMacroGenics3.5591 of 5 stars$1.59+11.2%$7.43+367.2%-65.0%$100.31M$148.34M-1.01430News CoveragePositive NewsAnalyst ForecastGap UpBDTXBlack Diamond Therapeutics3.3043 of 5 stars$1.75+6.7%$14.60+734.3%-59.2%$99.19MN/A-1.3290News CoveragePositive NewsCTNMContineum Therapeutics2.2008 of 5 stars$3.83-1.0%$23.75+520.1%-75.9%$99.09M$50M-0.7831Earnings ReportAnalyst ForecastENTXEntera Bio1.8093 of 5 stars$2.15flat$10.00+365.1%-20.1%$97.66M$181,000.00-8.2720News CoverageKYTXKyverna Therapeutics2.3629 of 5 stars$2.21+4.7%$18.33+729.6%-83.9%$95.51M$7.03M-0.6496News CoverageAnalyst RevisionGap DownOPTNOptiNose2.9829 of 5 stars$9.42+0.3%$9.00-4.5%-44.4%$95.09M$78.23M-2.24190News CoverageAnalyst ForecastAnalyst RevisionHLVXHilleVax2.4576 of 5 stars$1.89-0.5%$3.00+58.7%-86.9%$94.77MN/A-0.6120Positive NewsIMUXImmunic2.4114 of 5 stars$0.99-2.3%$13.20+1,237.8%-27.6%$94.54MN/A-0.8070Earnings ReportGap Down Related Companies and Tools Related Companies Sagimet Biosciences Alternatives Invivyd Alternatives MacroGenics Alternatives Black Diamond Therapeutics Alternatives Contineum Therapeutics Alternatives Entera Bio Alternatives Kyverna Therapeutics Alternatives OptiNose Alternatives HilleVax Alternatives Immunic Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DARE) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersWarning: Prepare to Be Shocked by These PayoutsThere's a strategy out there paying up to 70% on tech stocks like Amazon, Tesla, and Microsoft—stocks that don...Investors Alley | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredTrump’s treachery I think Trump’s Treasury Secretary is destroying the stock market on purpose. And no one on Wall Street see...Porter & Company | Sponsored🚨 Nvidia Just Inked a $7B AI Deal—This Could Change EverythingOn Wednesday, Nvidia stock surged—again. Why? Because Saudi Arabia just announced a multi-billion-dollar AI...Timothy Sykes | SponsoredSilver Is the New Oil—And the World’s Running DryElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Daré Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Daré Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy DARE Stock Free DARE Stock Alerts